Guardiant Reveal – pro
NCCN does not recommend this test for these purposes. The claim si that GuardiantReveal is the first blood-only test that is able to detect residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood to inform treatment decisions after surgery and detect recurrence as well. Currently, it is developed for early-stage colorectal cancer with testing for additional cancer types to follow.
This new test had not been prospectively studied and there is no consensus that it is standard of care.
Tsikitis, V.L., Larson, D.W., Huebner, M. et al. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14, 336 (2014). https://doi.org/10.1186/1471-2407-14-336
Parikh A, Van Seventer E, Siravegna G, Hartwig A, et al Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-21-0410